T1	intervention 15 74	recombinant human epidermal growth factor (EGF)-based cream
T2	condition 86 106	radiation dermatitis
T4	total-participants 444 446	40
T5	eligibility 447 518	breast cancer patients who received postoperative RT were prospectively
T6	control 633 677	general supportive skin care (control group)
T9	outcome 969 1018	radiation dermatitis of maximum grade 3, 2, and 1
T12	iv-bin-abs 1055 1056	6
T14	outcome 1124 1173	radiation dermatitis of maximum grade 3, 2, and 1
T17	cv-bin-abs 1210 1211	2
T19	outcome 1278 1319	incidence of grade 3 radiation dermatitis
T20	outcome 1479 1489	pain score
T10	iv-bin-abs 1032 1033	3
T21	iv-bin-percent 1035 1038	15%
T11	iv-bin-abs 1041 1043	11
T22	iv-bin-percent 1045 1048	55%
T15	cv-bin-abs 1187 1188	8
T23	cv-bin-percent 1190 1193	40%
T16	cv-bin-abs 1196 1198	10
T24	cv-bin-percent 1200 1203	50%
T18	cv-bin-percent 1222 1225	10%
T13	iv-bin-percent 1067 1070	30%
